Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Products under Development by Stage of Development | 8 | 1 |
| Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Products under Development by Therapy Area | 9 | 1 |
| Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Products under Development by Indication | 10 | 1 |
| Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Products under Development by Companies | 13 | 2 |
| Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Products under Development by Universities/Institutes | 15 | 2 |
| Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Therapeutics Assessment | 17 | 5 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 2 |
| Assessment by Route of Administration | 20 | 1 |
| Assessment by Molecule Type | 21 | 1 |
| Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Companies Involved in Therapeutics Development | 22 | 10 |
| Advinus Therapeutics Ltd | 22 | 1 |
| Amgen Inc. | 23 | 1 |
| Astellas Pharma Inc. | 24 | 1 |
| Caldan Therapeutics Limited | 25 | 1 |
| Connexios Life Sciences Pvt. Ltd. | 26 | 1 |
| Daiichi Sankyo Company, Limited | 27 | 1 |
| Hyundai Pharmaceutical Co., Ltd. | 28 | 1 |
| Japan Tobacco Inc. | 29 | 1 |
| Jiangsu Hengrui Medicine Co., Ltd. | 30 | 1 |
| Merck &Co., Inc. | 31 | 1 |
| Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Drug Profiles | 32 | 15 |
| AM-1638 Drug Profile | 32 | 1 |
| AM-3189 Drug Profile | 33 | 1 |
| AM-6226 Drug Profile | 34 | 1 |
| AS-2034178 Drug Profile | 35 | 1 |
| AS-2575959 Drug Profile | 36 | 1 |
| CNX-01167 Drug Profile | 37 | 1 |
| DS-1558 Drug Profile | 38 | 1 |
| HD-6277 Drug Profile | 39 | 1 |
| JTT-851 Drug Profile | 40 | 1 |
| MK-8666 Drug Profile | 41 | 1 |
| Small Molecule to Agonize GPR40 and GPR120 Receptors for Type 2 Diabetes Drug Profile | 42 | 1 |
| Small Molecule to Agonize GPR40 for Type 2 Diabetes Drug Profile | 43 | 1 |
| Small Molecule to Antagonize GPR40 for Obesity Drug Profile | 44 | 1 |
| Small Molecules to Agonize GPR40 for Diabetes Drug Profile | 45 | 1 |
| TUG-770 Drug Profile | 46 | 1 |
| Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Dormant Projects | 47 | 1 |
| Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Discontinued Products | 48 | 1 |
| Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Featured News &Press Releases | 49 | 2 |
| Apr 10, 2012: Connexios in discussions to partner early-stage GPR40 diabetes drug, CRO will be chosen in US/EU CEO | 49 | 1 |
| Jun 27, 2011: Connexios Life Science Presents Preclinical Data On CNX-011-67 At American Diabetes Association Meeting | 49 | 2 |
| Appendix | 51 | 2 |
| Methodology | 51 | 1 |
| Coverage | 51 | 1 |
| Secondary Research | 51 | 1 |
| Primary Research | 51 | 1 |
| Expert Panel Validation | 51 | 1 |
| Contact Us | 51 | 1 |
| Disclaimer | 52 | 1 |